Skip to main content
. 2019 Aug 23;79(14):1683–1691. doi: 10.1002/pros.23893

Figure 1.

Figure 1

Radium‐223 re‐treatment study design. aExploratory endpoints were calculated from start of radium‐223 re‐treatment. CRPC, castration‐resistant prostate cancer; inj, injection; mets, metastases; OS, overall survival; PSA, prostate‐specific antigen; SSE, symptomatic skeletal event; tALP, total alkaline phosphatase [Color figure can be viewed at wileyonlinelibrary.com]